We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court has reinstated a lawsuit against Warner-Lambert Co. by a group of Michigan residents who claim they suffered injuries as a result of their use of the diabetes drug Rezulin.
Friday, consumer products manufacturer Chattem Inc. said it agreed to acquire the U.S. rights to five leading consumer and over-the-counter brands from Johnson & Johnson and the consumer healthcare business of Pfizer Inc. for $410 million in cash.
While the U.S. heads the global pack in nanotechnology research, not enough money is being spent on studying the environmental, health and safety (EHS) risks nanotechnology presents, according to a report by the National Research Council assessing the National Nanotechnology Initiative (NNI) for Congress.
The FDA is withdrawing three electronic new drug application (NDA) and abbreviated new drug application (ANDA) guidances because the agency wants companies to adhere to a single format for submissions.
A group of federal agencies is joining forces with the drug industry to form a public-private partnership to search for new biomarkers in an effort to speed drug development and lower costs.
TorreyPines Therapeutics, Inc. announced the completion of its merger with Axonyx Inc. The combined company will operate as TorreyPines Therapeutics, Inc. under the leadership of TorreyPines' management team.